BioSpace

Australia's clinical trial advantage gains ground amid U.S. uncertainty

CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies aim to expand that advantage into a broader biotech ecosystem. The question remains whether Australia can support drug development at broader scale.

By BioSpace

1 min read
Australia's clinical trial advantage gains ground amid U.S. uncertainty
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights